Current and New Drug Treatments for Combined Diabetes and Obesity

Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dual GIP/GLP-1 receptor agonists may significantly reduce body mass index and visceral fat in patients with obesity and type 2 diabetes mellitus.

• The combination of obesity and type 2 diabetes mellitus contributes to severe metabolic dysfunction and increased cardiovascular and renal risks.
• Traditional treatment focusing only on blood sugar control does not adequately address the underlying issues of obesity and impaired glucose metabolism.
• Novel medications have shown dual benefits in both improving blood sugar levels and reducing body weight.
• These drugs operate through various mechanisms, including promoting glucose excretion, increasing feelings of fullness, slowing stomach emptying, and adjusting energy balance.
• Tirzepatide has been found to be more effective than single receptor agonists in enhancing metabolic health and body composition.
• Incorporating these treatments may help clinicians better manage the complex nature of obesity and diabetes, improving long-term health outcomes.

Simplified